Managing fibrosing interstitial lung disease (ILD) requires consistent antifibrotic use. However, gastrointestinal side effects often lead to early treatment cessation. Therefore, selecting the correct nintedanib initiation dose ILD specialists prescribe is essential for maintaining therapy. Consequently, a target-trial emulation recently investigated whether starting at 100 mg twice daily improves persistence compared to the standard 150 mg dose.

Benefits of the 100 mg Nintedanib Initiation Dose ILD

Specifically, the study analyzed 172 patients in a single-center cohort. In particular, researchers found that initiating treatment at 100 mg extended the 12-month restricted mean time on treatment by 52.9 days. Furthermore, the 12-month discontinuation risk was significantly lower in the 100-mg group compared to the 150-mg group. Consequently, this lower starting dose helps more patients stay on treatment longer. Moreover, this approach effectively addresses the common issue of early drug intolerance. Therefore, starting low may prevent permanent discontinuation.

Additionally, while lung function results were broadly similar between groups, the estimates for FVC %predicted were imprecise. However, clinicians should interpret these specific findings with caution. Nevertheless, the researchers advocated for a "start-low, escalate-as-tolerated" policy. Thus, such an approach might balance efficacy with tolerability more effectively for ILD patients. Because of this, patients experience better long-term adherence. Simultaneously, clinicians must monitor lung function carefully to ensure stability. In summary, the findings suggest a safer starting protocol for fibrosing ILD. Subsequently, prospective trials should validate these results. In contrast, standard dosing remains the baseline but requires more intensive side-effect management.

Frequently Asked Questions

Does a lower starting dose affect lung function?

The study indicated that changes in forced vital capacity (FVC) were broadly similar between the 100 mg and 150 mg initiation groups. However, the data were imprecise, and clinicians should monitor lung function closely regardless of the starting dose.

How much does a 100 mg starting dose improve persistence?

According to the emulation, starting at 100 mg extended the average time on treatment by nearly 53 days over a 12-month period. Additionally, it reduced the risk of complete treatment discontinuation significantly. Consequently, more patients were able to maintain their therapeutic regimen.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for medical concerns. Refer to the latest local and national guidelines for clinical practice.

References

Kaburaki S et al. Low-Dose vs. Standard-Dose Nintedanib at Initiation in Fibrosing ILD: A Target-Trial Emulation of Treatment Persistence and Lung Function. Ann Am Thorac Soc. 2026 Mar 22. doi: undefined. PMID: 41866291.

Richeldi L et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2071-2082.

Flaherty KR et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718-1727.